CD274 and Hodgkins lymphoma: Specifically, they conjugated anti-PD-L1 or atezolizumab, a PD-L1-blocking antibody, with M6Pn and tested their effects in the breast cancer cell line MBA-MB-231 and the Hodgkin’s lymphoma cell line HDLM-2, which expresses higher levels of CI-M6PR than the breast cancer model, respectively, observing a degradation of PD-L1 up to 70% [69].